Bedrocan to open a new cannabis production site in Denmark

Bedrocan, a Dutch company and Europe's medical cannabis flagship, is to expand its production capacity with the creation of a new GMP-certified facility for the cultivation and packaging of medical cannabis in Denmark. The new facility will be located in Køge, 30 kilometers south of Copenhagen.

Meeting international demand

The main reason for Bedrocan's expansion into Denmark is to better meet the growing international demand for its high-quality medicinal cannabis products. Under the current legal framework in the Netherlands, Bedrocan's products are only available through the Dutch Medicinal Cannabis Office (OMC), which is part of the Ministry of Health.

Bedrocan hopes to significantly improve the availability of its products for patients worldwide. In Denmark, Bedrocan will be able to do business directly with other commercial entities, in Europe and for export.

The new installation will comply with all relevant regulatory requirements (GACP and GMP). Products from this facility are initially intended to supply the European medical cannabis markets. The facility will employ around 40 people and will be operational by the end of 2023.

Products

The facility begins by producing some of Bedrocan's best-known varieties, such as the eponymous Bedrocan (a Jack Herer with 22% THC) and Bediol, as well as a new variety with high CBD content. Dried cannabis products are presented grinded (not whole flowers) in small and large packages.

For the manufacture of cannabis extracts and isolates, it will also be possible to obtain whole-plant cannabis from the Danish facility.